FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2103640416> ?p ?o ?g. }

• W2103640416 abstract "Background- The ability to consistently detect cell-free tumor-specific DNA in peripheral blood of patients with metastatic breast cancer provides the opportunity to detect changes in tumor burden and to monitor response to treatment. Studies of cell-free DNA in the peripheral blood of breast cancer patients suggest that methylated DNA markers in serum or plasma could be used for detection of advanced disease, monitoring of therapeutic response, and for early detection of disease recurrence.Methods- A genome-wide serum DNA methylome array (Illumina HumanMethylation27 BeadChip) analysis was conducted on cell-free circulating DNA in serum from women with stage IV recurrent breast cancer, and 232 key CpG loci were identified. Methylation for this panel of 10 gene loci was evaluated using our newly developed cMethDNA assay to detect miniscule amounts of methylated DNA in Training and Test sets of sera from a total of 112 women (n = 55 normal, n = 57 metastatic breast cancer). The clinical sensitivity and specificity of the assay, along with technical reproducibility, was determined. To evaluate the concordance of DNA methylation patterns, the 10 gene panel was tested on 22 DNA sets of primary tumor, metastases and serum from the same patient. Finally, the ability of cMethDNA to monitor response to therapy was evaluated in 28 patients with metastatic disease.Results- A normal laboratory threshold of 7 cumulative methylation units was set and assay parameters were locked, based on Receiver Operating Characteristic (ROC) analyses of DNA from 300 ul of patient sera in the Training set (normal, n = 28; cancer, n = 24; 92% sensitivity, 96% specificity, and AUC = 0.950). Evaluation of the Test set of patient sera (normal, n = 27; cancer n = 33) resulted in detection of metastatic breast cancer with 91% sensitivity, 100% specificity, and AUC = 0.994 (0.984-1.005, p<0.0001). Reproducibility of the cMethDNA assay increased with copy number; with the highest variation at 50 copies (CV = 29.1%) and the lowest at 3,200 copies (CV = 2.5%) of methylated DNA. The test was shown to be operator independent (ICC = 0.99). Evaluation of concordance between primary and disseminated tumor methylation showed that the methylation pattern from any given individual is highly conserved between serum, primary tissue and their metastases, and poorly conserved between different individuals. cMethDNA analysis of 28 patients before and after initiation of therapy showed a decrease in cumulative methylation in women with stable/responsive disease and a correlation with disease progression free survival (p<0.0001).Conclusion- Together, our data suggest that the cMethDNA test 1) can detect tumor DNA shed into blood, 2) reflect the methylation alterations typical of the primary tumor and its metastatic lesions, and 3) reflect response to treatment after chemotherapy. Next, we will test the clinical utility of cMethDNA in independent clinical trial sample sets where it's complementary and independent roles will be examined against CA15.3 and CTC assays.Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P2-06-01." @default.
• W2103640416 created "2016-06-24" @default.
• W2103640416 creator A5008003624 @default.
• W2103640416 creator A5023781047 @default.
• W2103640416 creator A5027207287 @default.
• W2103640416 creator A5035399830 @default.
• W2103640416 creator A5036494500 @default.
• W2103640416 creator A5041777150 @default.
• W2103640416 creator A5043125538 @default.
• W2103640416 creator A5049202057 @default.
• W2103640416 creator A5059553628 @default.
• W2103640416 creator A5065642142 @default.
• W2103640416 creator A5068418833 @default.
• W2103640416 creator A5069182401 @default.
• W2103640416 creator A5075892594 @default.
• W2103640416 creator A5088317474 @default.
• W2103640416 creator A5089489869 @default.
• W2103640416 creator A5089826071 @default.
• W2103640416 creator A5090416411 @default.
• W2103640416 date "2013-12-15" @default.
• W2103640416 modified "2023-09-27" @default.
• W2103640416 title "Abstract P2-06-01: cMethDNA is a quantitative circulating methylated DNA assay for detection of metastatic breast cancer and for monitoring response to therapy" @default.
• W2103640416 doi "https://doi.org/10.1158/0008-5472.sabcs13-p2-06-01" @default.
• W2103640416 hasPublicationYear "2013" @default.
• W2103640416 type Work @default.
• W2103640416 sameAs 2103640416 @default.
• W2103640416 citedByCount "0" @default.
• W2103640416 crossrefType "proceedings-article" @default.
• W2103640416 hasAuthorship W2103640416A5008003624 @default.
• W2103640416 hasAuthorship W2103640416A5023781047 @default.
• W2103640416 hasAuthorship W2103640416A5027207287 @default.
• W2103640416 hasAuthorship W2103640416A5035399830 @default.
• W2103640416 hasAuthorship W2103640416A5036494500 @default.
• W2103640416 hasAuthorship W2103640416A5041777150 @default.
• W2103640416 hasAuthorship W2103640416A5043125538 @default.
• W2103640416 hasAuthorship W2103640416A5049202057 @default.
• W2103640416 hasAuthorship W2103640416A5059553628 @default.
• W2103640416 hasAuthorship W2103640416A5065642142 @default.
• W2103640416 hasAuthorship W2103640416A5068418833 @default.
• W2103640416 hasAuthorship W2103640416A5069182401 @default.
• W2103640416 hasAuthorship W2103640416A5075892594 @default.
• W2103640416 hasAuthorship W2103640416A5088317474 @default.
• W2103640416 hasAuthorship W2103640416A5089489869 @default.
• W2103640416 hasAuthorship W2103640416A5089826071 @default.
• W2103640416 hasAuthorship W2103640416A5090416411 @default.
• W2103640416 hasConcept C104317684 @default.
• W2103640416 hasConcept C121608353 @default.
• W2103640416 hasConcept C126322002 @default.
• W2103640416 hasConcept C143998085 @default.
• W2103640416 hasConcept C150194340 @default.
• W2103640416 hasConcept C152110520 @default.
• W2103640416 hasConcept C153911025 @default.
• W2103640416 hasConcept C160798450 @default.
• W2103640416 hasConcept C172680121 @default.
• W2103640416 hasConcept C190727270 @default.
• W2103640416 hasConcept C203014093 @default.
• W2103640416 hasConcept C2775930923 @default.
• W2103640416 hasConcept C2778258057 @default.
• W2103640416 hasConcept C2778461978 @default.
• W2103640416 hasConcept C2779234561 @default.
• W2103640416 hasConcept C2779823535 @default.
• W2103640416 hasConcept C502942594 @default.
• W2103640416 hasConcept C530470458 @default.
• W2103640416 hasConcept C54355233 @default.
• W2103640416 hasConcept C71924100 @default.
• W2103640416 hasConcept C86803240 @default.
• W2103640416 hasConceptScore W2103640416C104317684 @default.
• W2103640416 hasConceptScore W2103640416C121608353 @default.
• W2103640416 hasConceptScore W2103640416C126322002 @default.
• W2103640416 hasConceptScore W2103640416C143998085 @default.
• W2103640416 hasConceptScore W2103640416C150194340 @default.
• W2103640416 hasConceptScore W2103640416C152110520 @default.
• W2103640416 hasConceptScore W2103640416C153911025 @default.
• W2103640416 hasConceptScore W2103640416C160798450 @default.
• W2103640416 hasConceptScore W2103640416C172680121 @default.
• W2103640416 hasConceptScore W2103640416C190727270 @default.
• W2103640416 hasConceptScore W2103640416C203014093 @default.
• W2103640416 hasConceptScore W2103640416C2775930923 @default.
• W2103640416 hasConceptScore W2103640416C2778258057 @default.
• W2103640416 hasConceptScore W2103640416C2778461978 @default.
• W2103640416 hasConceptScore W2103640416C2779234561 @default.
• W2103640416 hasConceptScore W2103640416C2779823535 @default.
• W2103640416 hasConceptScore W2103640416C502942594 @default.
• W2103640416 hasConceptScore W2103640416C530470458 @default.
• W2103640416 hasConceptScore W2103640416C54355233 @default.
• W2103640416 hasConceptScore W2103640416C71924100 @default.
• W2103640416 hasConceptScore W2103640416C86803240 @default.
• W2103640416 hasLocation W21036404161 @default.
• W2103640416 hasOpenAccess W2103640416 @default.
• W2103640416 hasPrimaryLocation W21036404161 @default.
• W2103640416 hasRelatedWork W1969278255 @default.
• W2103640416 hasRelatedWork W1973684950 @default.
• W2103640416 hasRelatedWork W2000122269 @default.
• W2103640416 hasRelatedWork W2014666761 @default.
• W2103640416 hasRelatedWork W2036868786 @default.
• W2103640416 hasRelatedWork W2317930154 @default.
• W2103640416 hasRelatedWork W2362899688 @default.
• W2103640416 hasRelatedWork W2531153177 @default.
• W2103640416 hasRelatedWork W2617035794 @default.
• W2103640416 hasRelatedWork W2777534716 @default.

• next